Testosterone Cypionate Cost in Wisconsin (2026): Cash, Insurance, and Compounded Pricing

Testosterone cypionate is a generic injectable ester of testosterone (brand reference: Depo-Testosterone), classified as a Schedule III controlled substance and available only by prescription. It is FDA-approved as replacement therapy for males with hypogonadism caused by confirmed testicular, pituitary, or hypothalamic disease. It is not FDA-approved for age-related low testosterone, athletic performance, or off-label uses in women, though clinicians sometimes prescribe it off-label for those purposes.

The direct answer: what a Wisconsin patient pays for testosterone cypionate depends far more on which access pathway they use, cash pharmacy with a discount card, commercial insurance formulary tier, Medicaid prior authorization, a compounding pharmacy, or a telehealth bundle, than on the drug itself, since the medication has been off-patent and generically available for decades. National discount-card platforms and pharmacy chains commonly publish cash prices for a standard 200 mg/mL injectable vial in the range of roughly $30 to $90 per month depending on vial size and pharmacy, but HealthRX.com does not have a verified, dated, Wisconsin-specific price survey to confirm an exact statewide average, and any number presented as a precise Wisconsin figure should be treated as unconfirmed until checked directly with a specific pharmacy on a specific date.

What is actually established, and what is not

Established (regulatory and clinical facts that do not change with the calendar year):

• Testosterone cypionate is FDA-approved for male hypogonadism due to confirmed structural or organic disease, not for normal age-related testosterone decline. Full labeling is searchable through the FDA's drug label database.
• It is a Schedule III controlled substance, requiring a prescription and subject to controlled-substance dispensing rules.
• Compounded testosterone cypionate from a state-licensed 503A pharmacy is legal under federal law when made for an individual patient with a valid prescription, but compounded products are not FDA-approved and do not go through FDA's efficacy and manufacturing review.
• Guideline bodies, including the Endocrine Society, recommend confirming hypogonadism with repeated low morning total testosterone measurements before starting therapy, and monitoring hematocrit, PSA (in appropriate age groups), and testosterone levels during treatment. See The Endocrine Society for current practice guidance.
• Testosterone therapy suppresses sperm production and is generally not recommended for men actively trying to conceive; this is a mechanism-based, well-documented effect rather than a controversial claim.

Plausible but not verifiable from the material available for this page:

• Any specific cash-pay dollar figure for Wisconsin specifically (a statewide average, a Costco price, a compounding pharmacy price). National discount aggregators publish ranges that shift by pharmacy and month; nothing in the sourcing behind this page constitutes a dated, Wisconsin-specific price survey.
• Specific copay amounts or prior-authorization turnaround times for named Wisconsin insurers (Quartz, Group Health Cooperative, Dean Health Plan, Anthem BCBS Wisconsin) or for Wisconsin Medicaid. Formulary tiers and PA rules change on plan renewal cycles, typically annually, and sometimes mid-year.
• The precise magnitude of 340B pricing discounts at Wisconsin federally qualified health centers. 340B pricing exists as a federal program (see HRSA's 340B program page), but the specific percentage discount for this drug at a specific Wisconsin site is not something this page can confirm.

Not established:

• That compounded testosterone cypionate is cheaper, safer, or clinically equivalent to FDA-approved manufactured product for most patients. Cost and formulation differences exist, but compounded products lack FDA review of manufacturing consistency and are not interchangeable with approved generics as a matter of regulatory equivalence.

Does Wisconsin Medicaid cover testosterone cypionate?

Wisconsin Medicaid (administered as BadgerCare Plus for many enrollees) can cover testosterone cypionate for documented male hypogonadism, and Medicaid programs generally require prior authorization with lab and symptom documentation for testosterone products. That structure is consistent with how state Medicaid pharmacy benefit managers typically handle controlled substances used for a chronic, lab-confirmed diagnosis. The exact current PA criteria, turnaround time, and copay for Wisconsin Medicaid in 2026 should be confirmed directly with the state's Medicaid pharmacy benefit administrator or at Medicaid.gov, since these operational details are not published in a form this page can verify and cite precisely.

Private insurance in Wisconsin

Commercial plans sold in Wisconsin generally place generic injectable testosterone on a preferred generic tier, and prior authorization or step therapy documenting a hypogonadism diagnosis is common across payers nationally. Naming specific Wisconsin insurers' current copay amounts, tier placement, or PA thresholds as fixed facts would overstate what can be confirmed without a live formulary lookup, because formularies are re-negotiated on an annual basis and sometimes change mid-year. Patients should call the number on their insurance card or check their plan's current formulary document rather than rely on a general estimate.

Compounded testosterone cypionate: what the legal distinction means for cost

Compounded testosterone cypionate from a Wisconsin-licensed 503A pharmacy is legally available with a valid prescription, and pharmacies compounding sterile injectables must follow USP <797> standards and state board of pharmacy oversight. Patients sometimes choose compounded formulations for a different carrier oil, a non-standard concentration, or a larger multi-dose vial. The tradeoff is regulatory: compounded drugs are not FDA-approved, do not undergo FDA premarket review, and quality can vary by pharmacy, so verifying a specific compounding pharmacy's current state licensure and inspection history matters more than comparing an advertised price alone.

Telehealth prescribing in Wisconsin

Wisconsin permits telehealth prescribing of controlled substances, including Schedule III testosterone cypionate, when a prescriber establishes a legitimate patient relationship, which commonly includes a synchronous audio-video visit and review of lab work. An out-of-state clinician cannot legally prescribe to a Wisconsin patient without holding a Wisconsin medical license and a Wisconsin-registered DEA number. Telehealth platform pricing for the consultation itself (separate from the medication) varies by company and is not something this page can quote as a fixed, current figure; platform pricing pages should be checked directly at the time of use, since telehealth pricing changes more often than clinical guidance does.

Clinical facts that affect the real cost of treatment, not just the drug price

The prescribed weekly dose is the single largest driver of monthly medication cost, since a patient on 200 mg per week uses roughly twice the vial volume of a patient on 100 mg per week. Beyond the drug itself, ongoing monitoring is part of the real cost of testosterone therapy: guideline-recommended baseline and follow-up labs include total testosterone, hematocrit, and (in men over 40) PSA, generally checked at 3 to 6 months after starting therapy and at least annually thereafter. Elevated hematocrit (polycythemia) is a recognized and relatively common adverse effect of testosterone therapy that can require dose reduction or discontinuation, which is why hematocrit monitoring is not optional. Men who are actively trying to conceive should discuss fertility-preserving alternatives (such as clomiphene citrate or hCG) with their prescriber before starting testosterone, since exogenous testosterone suppresses natural sperm production through feedback on the hypothalamic-pituitary-gonadal axis; this is an established mechanism, not a theoretical risk.

A single randomized, controlled clinical trial program in older men with confirmed low testosterone (widely referred to in the literature as the T-Trials) has been reported to show symptomatic improvements with testosterone gel over one year compared to placebo. The exact effect sizes and safety findings from that program should be verified against the original publication before being cited as a specific number, since the identifier for that trial was not independently confirmed for this page.

When to seek urgent care rather than adjust dosing yourself

Chest pain, shortness of breath, calf swelling and pain, sudden severe headache, or symptoms of a stroke are not something to manage by changing an injection schedule; these require emergency evaluation. Because testosterone therapy can affect red blood cell counts, any new symptoms of hyperviscosity (severe headache, vision changes, unusual clotting) after starting therapy should prompt an urgent call to the prescribing clinician rather than waiting for a scheduled follow-up.

Verification checklist: what is stable versus what you must confirm locally and by date

Use this before assuming a price, coverage rule, or legal detail applies to your situation.

Stable facts (federal regulatory or clinical standard, unlikely to change month to month):

• FDA-approved indication is male hypogonadism from confirmed organic disease, not general age-related decline, confirm via the FDA label database
• Testosterone cypionate is a Schedule III controlled substance requiring a valid prescription
• Compounded product legality rests on 503A federal rules plus state pharmacy board licensure, confirm via the state board of pharmacy and applicable federal compounding rules
• Guideline-recommended baseline and follow-up labs (testosterone, hematocrit, PSA where applicable), confirm current recommendations at The Endocrine Society
• Fertility suppression is a known mechanism-based effect, relevant if conception is planned

Date-sensitive facts (must be reconfirmed at the time of use, not assumed from any article):

• Cash price at your specific pharmacy, for your specific vial size and concentration, today
• Whether your discount card (GoodRx, RxSaver, manufacturer card) is currently accepted at that pharmacy and what it actually charges after running it
• Your insurer's current formulary tier, copay, and prior-authorization requirement for testosterone cypionate this plan year
• Wisconsin Medicaid or BadgerCare Plus current prior-authorization criteria and processing time, confirm at Medicaid.gov or directly with the state pharmacy benefit administrator
• Whether a specific compounding pharmacy currently holds active Wisconsin licensure and passed its most recent inspection
• Whether a specific telehealth platform's prescriber is licensed in Wisconsin and holds a Wisconsin DEA registration
• Whether a specific 340B site's discount applies to your prescription and what the discounted price actually is this month

If a number cannot be checked against one of the stable sources above or confirmed directly with the payer, pharmacy, or clinic today, treat it as an estimate rather than a fact.

Evidence gaps in this page

This draft does not include specific Wisconsin cash-price averages, specific insurer copay figures, specific Medicaid PA turnaround times, or specific 340B discount percentages, because no dated, Wisconsin-specific primary source was available to verify those numbers. Readers who need an exact number for a specific insurer, pharmacy, or Medicaid decision should get it directly from that plan, pharmacy, or state agency rather than from a general cost article. Claims attributed above to specific clinical trials (the older-men testosterone trial program, a telehealth outcomes study, an out-of-pocket cost trend study) describe findings reported elsewhere in the literature; a qualified reviewer should confirm the original publications before any specific effect size or percentage from those studies is restored to this page.

References

1. U.S. Food and Drug Administration. Drug label and approval database (search for testosterone cypionate injection). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. The Endocrine Society. Clinical practice resources on testosterone therapy. https://www.endocrine.org/
3. Health Resources and Services Administration. 340B Drug Pricing Program. https://www.hrsa.gov/opa
4. Medicaid.gov. State Medicaid program information. https://www.medicaid.gov/